Neoplasms clinical trials

The registry lists 10,818 studies for Neoplasms across more than 10 countries. 2,324 are recruiting or about to start. 5,791 of them are mainly about Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 377 narrower conditions too, such as Breast Neoplasms: 113,122 studies, 27,650 open.

ClinicalTrials.gov finds 124,629 studies for Neoplasms. How that becomes 10,809 here

This page counts the studies the registry files under Neoplasms, and those it files under no condition that list Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

124,629Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−100,176Filed under a narrower condition, counted on its own pageBreast Neoplasms 12,819 · Carcinoma, Non-Small-Cell Lung 6,345 · Prostatic Neoplasms 5,595 · Colorectal Neoplasms 4,986 · Multiple Myeloma 3,382 · Leukemia, Myeloid, Acute 3,119 · 339 more
−7,126List Neoplasms as a condition, but the registry did not file them under itMost often written as “Advanced Solid Tumors” (533), “Solid Tumor” (495), and “Unspecified Adult Solid Tumor, Protocol Specific” (461). The registry filed 5,391 of them under no condition at all, and the others under other conditions only, most often Cancer Pain (131) and Pain (93).
−6,518Match it another way4,305 name it in the title, 456 in a keyword, and 1,757 by a synonym or other text the search reads.
10,809The count on this page

Status

Completed: 5,530
Recruiting: 1,718
Terminated: 1,018
Status unknown: 940
Active, not recruiting: 597
Not yet recruiting: 500

Phase

Phase 1: 2,627
Phase 2: 1,981
Phase 3: 656
Phase 4: 205
Early Phase 1: 122

Where

United States: 4,949
France: 1,207
United Kingdom: 833
Canada: 827
China: 753
Spain: 713

Who runs them

National Cancer Institute (NCI) (265) · M.D. Anderson Cancer Center (164) · GlaxoSmithKline (136) · AbbVie (129) · AstraZeneca (106) · Novartis Pharmaceuticals (100) · Memorial Sloan Kettering Cancer Center (87) · Bayer (80)

What is being tested here

Drugs under test in Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Pembrolizumab	14	4	40
Bevacizumab	9	7	69
Atezolizumab	9	9	30
Trastuzumab	8	4	16
Dexamethasone	7	9	34
Nivolumab	7	2	27
Olaparib	7	2	24
Cobimetinib	6	2	13
Pertuzumab	6	3	10
Gallium-68	6	0	8

Drug classes tested here Immune checkpoint inhibitors 69 open · Tyrosine kinase inhibitors (TKIs) 41 open · Antimetabolites 20 open · Angiogenesis inhibitors 15 open · PARP inhibitors 15 open

Coming up

147phase 3 studies under way

852studies finish main data collection within a year42 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026PREVENT HPV -Related Cancers Trial · Phase 3 · University of Utah
Nov 2026Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms · Phase 3 · Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Nov 2026Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms · Phase 3 · Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Nov 2026A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer · Phase 3 · Tesaro, Inc.
Nov 2026A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) · Phase 3 · Hoffmann-La Roche
Dec 2026Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters · Phase 3 · Ottawa Hospital Research Institute
Dec 2026Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy · Phase 3 · Blokhin's Russian Cancer Research Center
Dec 2026Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer. · Phase 3 · Ain Shams University
Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) · Phase 3 · Qilu Pharmaceutical Co., Ltd.
Dec 2026Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab · Phase 3 · AstraZeneca

Who these studies take

Of the 1,718 Neoplasms studies recruiting now, 1,176 (68%) set no upper age limit and 330 (19%) stop at 75 or younger. 336 (20%) take children under 18. 90 (5%) are for women only and 35 (2%) for men only; 228 (13%) take healthy volunteers.

Recruiting studies that take each age, of 1,718
Age	Women	Men
10	262 (15%)	256 (15%)
18	1,496 (87%)	1,464 (85%)
30	1,468 (85%)	1,419 (83%)
40	1,465 (85%)	1,416 (82%)
50	1,470 (86%)	1,427 (83%)
65	1,487 (87%)	1,441 (84%)
75	1,446 (84%)	1,406 (82%)
85	1,289 (75%)	1,255 (73%)

Across all 10,818 studies, recruiting or not: 18% stop at 75 or younger and 12% at 65; 17% take children; 7% are for women only and 3% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neoplasms studies take

Of 903 phase 1 interventional studies under Neoplasms, half reached primary completion within 40 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	40 mo23–64 · 903 studies	38 mo22–61 · 677 studies	48 mo28–88 · 226 studies
Phase 1/2	60 mo39–89 · 296 studies	61 mo41–88 · 194 studies	59 mo33–111 · 102 studies
Phase 2	52 mo33–92 · 514 studies	42 mo26–68 · 179 studies	58 mo36–99 · 335 studies
Phase 2/3	44 mo28–90 · 47 studies	—	—
Phase 3	50 mo33–84 · 202 studies	44 mo30–72 · 119 studies	60 mo43–96 · 83 studies
Phase 4	38 mo21–64 · 88 studies	—	33 mo21–56 · 64 studies
Interventional, no phase	29 mo13–52 · 2,056 studies	23 mo11–53 · 75 studies	29 mo13–52 · 1,981 studies
Observational	58 mo24–210 · 1,246 studies	47 mo29–102 · 148 studies	61 mo24–227 · 1,098 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out